EU MDR GSPR 10 Biocompatibility Technical Documentation Pack
Help medical-device teams build a device-specific, source-dated, traceable GSPR 10 evidence record that connects exact legal subclauses to final-finished-device facts, controlled evidence, methods, risk and clinical files, post-market information, technical-documentation locations, actions, and qualified conclusions.
Package at a glance
11 ZIP entries
The current customer archive passed exact-inventory, checksum, and deterministic-rebuild QA.
18 workbook sheets
A fail-closed working system with sample content kept separate.
3-page Quick Start
A concise route through the files, controls, and escalation points.
30 official sources
Source status, limitations, retrieval dates, and recheck triggers.
A traceable working record—not a shortcut to a conclusion
Clause-accurate chemical, physical, and biological evidence mapping for MDR Annex I Section 10 and Annex II
Clause-Accurate GSPR 10 Map
A clause-accurate map of MDR Annex I Sections 10.1 through 10.6, including every 10.1 factor and the distinct duties in 10.3, 10.4.1 through 10.4.5, 10.5, and 10.6.
CMR/ED Trigger and Justification
A controlled device and supplied-state baseline covering intended purpose, configurations, direct and indirect contact, materials, substances, processes, residues, particles, ingress pathways, packaging, sterilization, ageing, and use conditions.
Evidence-to-Annex II Traceability
A component-level material and contact record tied to the exact final-finished device rather than generic material names or unbounded supplier declarations.
Fail-Closed Qualified Review
A fail-closed CMR and endocrine-disruptor gate that separates device/part scope, concentration evidence, current classification status, exposure, alternatives, vulnerable groups, guideline review, labeling, and IFU actions.
What the current customer edition contains
The verified v3.0 archive contains 9 buyer payload files plus MANIFEST.csv and SHA-256 checksums. Final document, workbook, visual, and archive-integrity QA are complete.
Quick Start PDF
Freeze the candidate, follow the safe sequence, identify source rechecks, and recognize legal/scientific stop conditions before drafting conclusions.
Complete when: The team knows the exact device, intended purpose, variants, supplied state, MDR baseline, roles, source date, review order, and reserved decisions.
Implementation Guide PDF
Understand every current GSPR 10 clause, the CMR/ED gate, evidence appraisal, standards distinctions, lifecycle links, and Annex II navigation.
Complete when: The team can explain each requirement, device fact, method, evidence item, limitation, action, and approval without relying on a score or generic biocompatibility claim.
Editable Working Templates DOCX
Draft the charter, clause map, material/contact baseline, process/compatibility records, CMR/ED gate, justification, evidence bridges, locators, and release memo.
Complete when: Every entry is device specific; all uncertainty, contrary data, and missing evidence has an owner, action, due date, and decision path.
Operational Workbook XLSX
Control the atomic GSPR map, device facts, evidence, standards status, red flags, actions, decisions, precise locators, and fictional training trace.
Complete when: No invalid or incomplete control remains; open/blocked actions are resolved; every terminal row has evidence, rationale, decision, reviewer/competence, date, and trigger.
Source Status and Release Notes PDF
Verify current MDR, 2025 amendment, 2026 harmonisation acts/corrigendum, ECHA/SCHEER status, dynamic classifications, and ISO/EN/OJ distinctions.
Complete when: The register matches the exact official sources and controlled standards used for the candidate decision on the recorded date.
Customer README, responsible-use terms, and official source register
Orient recipients, preserve identity and version, control authorized use, and make update obligations explicit.
Complete when: Product/workbook IDs, version, files, source date, support route, and professional boundaries agree across the package.
Inspect the actual working system
These are direct renders of the current v3.0 workbook prepared as public product views, not marketing mock-ups. Select any image to inspect it at full size.
How the resource is intended to be used
The complete Quick Start and implementation guide are included in the current v3.0 customer edition. This public walkthrough lets a buyer inspect the operating logic and stop conditions before requesting an exact offer.
Controlled assessment charter
Freeze one exact MDR device candidate, intended purpose, variants, supplied state, markets, certificate status, source date, and decision request.
Stop if: The candidate, intended purpose, certification baseline, or decision owner is unclear.
GSPR 10 clause map
Map Sections 10.1 through 10.6 exactly; record applicability or a device-specific not-applicable rationale for each atomic control.
Stop if: Clauses are paraphrased into a generic biocompatibility checklist or 10.3, 10.5, and 10.6 are conflated.
Device, material, and exposure baseline
Reconstruct the final-finished device, material/substance inventory, direct and indirect contacts, processing, contamination, residues, particles, ingress pathways, and use conditions.
Stop if: A patient/user-contact pathway, formulation, process, surface, supplied state, or affected configuration is unknown.
CMR/endocrine-disruptor gate
Run the 10.4 scope and concentration gate using controlled substance identity, current classification evidence, concentration, affected part, and intended use.
Stop if: Identity, concentration basis, classification source, or device/part scope is incomplete.
10.4 justification and information package
When 10.4.1 is triggered, document exposure, alternatives, functionality and benefit-risk argumentation, vulnerable groups, current guidelines, labeling, and IFU controls.
Stop if: A justification omits alternatives, exposure, vulnerable populations, labeling, or qualified approval.
Evidence and method-status register
Index complete controlled evidence, methods, representative articles, findings, deviations, limitations, and exact technical-documentation locations.
Stop if: Only summaries, certificates, declarations, report titles, or unsupported compliance statements are available.
Technical-documentation evidence bridge
Bridge every clause to risk, biological evaluation, chemistry/toxicology, clinical, PMS/PMCF, labeling, and Annex II records; reconcile contrary information.
Stop if: A favorable conclusion is isolated from risk, clinical, post-market, or contradictory evidence.
Controlled review candidate
Reverify current official sources, close or formally block actions, remove fictional records, and route the exact release candidate through qualified and independent review.
Stop if: A source changed, a stop flag remains, a required approval is absent, or files disagree on identity or status.
Current public authorities behind the working controls
Sources were checked 2026-08-02; next planned portfolio recheck is 2026-11-02. Live status must still be verified at each material decision or submission event.
European Union · Consolidated Regulation (EU) 2017/745, current 1 January 2026
In-force consolidated text incorporating Regulation (EU) 2025/2457. Use the Official Journal acts for legal certainty and recheck for later amendments.
European Union · Regulation (EU) 2025/2457 amending MDR and IVDR
In force from 1 January 2026 for the relevant amendments. It revised Annex I 10.4 endocrine-disruptor references and assigned guideline preparation/update to ECHA.
European Union · Consolidated Implementing Decision (EU) 2021/1182, current 17 June 2026
In-force consolidated MDR harmonised-standards list. It is the authority record for OJ harmonisation, not a substitute for the standard or a device-specific applicability decision.
European Union · Commission Implementing Decision (EU) 2026/1231
In force; published 17 June 2026. It added EN ISO 10993-1:2025 and EN ISO 10993-5:2009/A11:2025 and updated harmonised references for Parts 12, 17, and 23.
European Union · Corrigendum to Implementing Decision (EU) 2026/1231
Official corrigendum published 22 June 2026. It changes the application date for Annex point (5) from 15 June 2031 to 17 June 2031.
ECHA · ECHA's role in medical devices
Official dynamic explanation of ECHA's post-2025 role. It notes the 2024 SCHEER phthalate update and an expected next revision in 2029 or earlier if requested.
What the resource deliberately does not promise
Clear boundaries protect the buyer and make the working records more useful to qualified reviewers.
Clear boundary 1
No automated legal applicability, conformity, biological-safety, toxicological-acceptability, test-selection, no-new-test, or representative-article decision.
Clear boundary 2
No automated CMR/endocrine-disruptor identity, classification, threshold, exposure, alternatives, vulnerable-group, labeling, or IFU conclusion.
Clear boundary 3
No notified-body, competent-authority, certificate, submission, CE-marking, implementation, or market-release decision.
Clear boundary 4
No universal coverage of IVDs, combination products, medicinal substances, tissues/cells, animal derivatives, degradable/resorbable devices, nanomaterials, reusable processing, implants, or other specialist technologies without additional expertise.
Questions to settle before requesting an offer
Is the current v3.0 edition available?
Yes. The current v3.0 customer edition is released and available by request. Online checkout, payment, customer download, and automatic delivery are not currently enabled. Use Request Exact Offer to receive the controlled offer before deciding whether to pay.
What is included in the current v3.0 edition?
The verified archive contains 11 ZIP entries: 9 buyer payload files plus MANIFEST.csv and SHA-256 checksums. It includes a 3-page Quick Start, 21-page implementation guide, 23-page editable templates, and 18-sheet workbook. Final document, workbook, visual, and archive-integrity QA are complete.
Does the resource provide a completed regulatory or biological conclusion?
No. It provides a traceable working system. Device-specific conclusions, testing decisions, toxicological judgments, and submission decisions require qualified review.
Can I inspect the product before requesting an offer?
Yes. This page shows the complete workflow and real v3.0 product views, while the downloadable 5-page public preview explains the scope, operating logic, included files, and important limits.
EU MDR GSPR 10 Biological-Evaluation Pressure Points
See where chemical, physical and biological evidence commonly loses traceability across Annex I, risk management and technical documentation.
Review the workflow now. Request the exact current offer.
No order, payment, customer download, or delivery is created through this page. The controlled offer identifies the exact version, licence, price, update option, policies, and delivery method for your review before any payment decision.